IRB Study Number 23-1220
Status Recruiting
Phase Phase 3
Location Cleveland Clinic Main Campus
Institute Endocrinology and Metabolism Institute
Description
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease and type 1 diabetes.
Inclusion Criteria
- Participants must be ++18 years of age or older++
- Participants with T1D continuously treated with insulin started within 1 year from diagnosis
- HbA1c <10%
- K+ ≤4.8mmol/L at screening
- Participants with Chronic Kidney disease with both of the criteria- eGFR ≥25 to ≤90 mL/min/1.73 m2, and UACR≥200mg/g to <5000mg/g at the screening visit.
